TG Therapeutics Inc.’s (TGTX) Ublituximab, proposed for the treatment of patients with relapsing forms of multiple sclerosis, is at the FDA altar, with a decision due on December 28, 2022.Ublituximab, previously known as TG-1101, is an investigational glycoengineered monoclonal antibody that works by targeting CD20, a protein expressed on the surface of B cells. As you may be aware that B cells are a type of white blood cell and they are said to play a role in the pathogenesis of multiple sclerosis.The company sees a blockbuster market opportunity for Ublituximab, if approved.TGTX closed Friday’s trading at $8.11, down 0.73%.